
Debut, an innovator in beauty biotechnology has announced the launch of BeautyORB, an artificial intelligence (AI)-powered ingredient discovery platform. This technology is reportedly set to transform beauty product innovation globally, leveraging pharmaceutical-grade methodologies to introduce two high-performance biotech ingredients annually.
Advanced Ingredient Innovation
BeautyORB has already fueled the creation of three groundbreaking ingredients—some of which are up to 15x more effective than the current market offerings—addressing concerns like inflammaging, epidermal barrier repair, and longevity. These include:
- DermCeutical InflamagePRO
- DermCeutical Barrier RepairPRO
- DermCeutical LongevityPRO
These ingredients not only surpass existing efficacy benchmarks, per the company, but also establish new standards in addressing critical skin care needs. Looking ahead, Debut's innovation pipeline is actively exploring biotech solutions for brightening, anti-aging, and scalp care—ensuring a steady flow of high-performing, sustainable ingredients for the beauty industry.
How It Works
BeautyORB uses AI to generate the best-performing novel ingredients for novel claim areas, from a typical time of 3-5 years to two ingredients launched per year. This innovation engine examines the effects that compounds have on skin biology and discovers new pathways for enhanced clinical claims.
The new tool leverages:
- More than 50 billion molecule possibilities
- 30,000 genes tested per molecule using omics technology
- 25,000 genes tested per second
- 21,000 molecules screened in silico per second for deep learning
- 200+ new biological pathways tested per molecule
- Over 60 million data points, with 100 million over the next 12 months
Shaping the Future of Beauty Innovation
Joshua Britton, Ph.D, founder and CEO of Debut says, “With our advanced AI platform and understanding of skin biology, we can rapidly create brand new ingredients through computational compound prediction. This allows us to activate specific aspects of skin biology while also discovering new or improved cellular pathways for enhanced clinical claims. We don’t have to rely on an array of existing ingredients to test against specific claims, and we don’t have to go into the field to find rare ingredients in plants. All this can be done at the click of a button, cutting out years from the innovation cycle and accessing ingredients that no one has seen before. We can turn on and off molecular pathways differently and use AI to discover what molecules can affect those pathways. The result is a rich, proven and growing pipeline of novel ingredients with the strongest clinical results for our customers, allowing brands to win on product performance rather than marketing.”
Britton adds, “With BeautyORB, we can develop ingredients that have the targeted responses we seek, using the same technology to find ingredients that fight disease. Our tool is another key step in the convergence of pharma and beauty. We are thrilled to partner with the industry leading contract manufacturer KDC/one to create finished products of the highest quality, in tandem with Debut’s custom formulation business, BiotechXBeautyLabs, to achieve our mission of reinventing product performance with the safest sustainability credentials. Our KDC/one partnership sets the stage for a global biomanufacturing revolution in beauty.”